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(back) (left to right)doi:10.1016/j.jtcvs.2005.10.008Objectives: Surgical ventricular reverse remodeling has been shown to possibly
improve hemodynamics and symptoms, but effects on long-term mortality are not
established. No consistent data are available on which patients will benefit most
from this procedure. This study was designed to analyze the predictors of long-term
survival after surgical ventricular reverse remodeling in patients with ischemic
cardiomyopathy.
Methods: Eighty-five patients who underwent surgical ventricular reverse remod-
eling between May 1991 and October 2003 were retrospectively analyzed. Left
ventricular wall motion and left ventricular equatorial diameter were assessed by
means of angioventriculography. Left ventricular ejection fraction and volumes
were measured by means of echocardiography. Cox regression analysis was used in
several combinations to create a final model for identifying predictors of death.
Results: Actuarial survival after 1, 3, 5, and 10 years was 89%, 79%, 75%, and 75%,
respectively. New York Heart Association class improved from 2.9  1.0 to 1.3 
0.5 (P  .0001), left ventricular ejection fraction increased from 27.6%  6.3% to
43.0%  10.1% (P  .0001), and left ventricular end-systolic volume index
decreased from 89.6 27.6 mL/m2 to 56.5 34.5 mL/m2 (P .0001). Multivariate
analysis identified left ventricular equatorial diameter of 70 mm or greater (hazard
ratio, 5.28; 95% confidence interval, 1.79-11.71; P  .020) and segmental akinesia
(hazard ratio, 4.46; 95% confidence interval, 1.23-17.12; P  .024) as the only
independent predictors of death.
Conclusions: In this analysis of a single cohort of patients, surgical ventricular
reverse remodeling improves the symptoms of ischemic cardiomyopathy, as well as
left ventricular function, shape, and volume, with encouraging long-term outcomes,
particularly in patients with dyskinesia. A left ventricular equatorial diameter of 70
mm or greater appears to be an important independent prognostic factor, which
suggests the relevance of the left ventricular equatorial region for effective surgical
reverse remodeling.
Coronary artery disease is the most frequent cause of heart failure (HF) inWestern countries.1 Despite improvements with medical treatment, theprognosis of patients with end-stage HF remains poor.2 Although heart
transplantation is the best option for end-stage cardiomyopathy, this treatment is
limited by a shortage of donors. Furthermore, in the subgroup with ischemic
cardiomyopathy, both mortality on the waiting list and long-term results of heart
transplantation are worse than in patients with idiopathic dilated cardiomyopathy.3,4
These factors contributed to the development of surgical techniques with the aim of
improving the function of the left ventricle. Left ventricular (LV) surgical reverse
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surgical remodeling and ventricular reshaping) or surgical
ventricular restoration5 has been found to improve symp-
toms and ventricular function in patients with ischemic
cardiomyopathy.6,7 This operative method benefits patients
with akinesia or dyskinesia of anterior LV segments and
decreased LV function by reducing ventricular wall stress
and restoring the spherical left ventricle to a more physio-
logic elliptical shape.8 A recent registry of 1198 SVR pro-
cedures performed in 13 centers worldwide indicates en-
couraging results.9 In this study different surgical teams
used a variety of surgical techniques, and follow-up time
was limited to 5 years. The ongoing Surgical Treatment for
Ischemic Heart Failure trial was designed to address open
and controversial issues about SVR in patients with HF.10
We thought it would be worth reviewing our series of SVR
before we entered this trial in November 2003 to identify
any factors that could help in predicting outcomes. Because
this series represents our whole 12-year experience with
SVR, it might also provide some useful long-term follow-up
information.
Methods
Patient Population
Between May 1991 and October 2003, 122 patients with LV
dysfunction caused by coronary artery disease underwent SVR.
Excluded from the analysis were patients with posterior akinetic or
dyskinetic LV segments (n  18), patients with an LV ejection
fraction (LVEF) of greater than 35% (n 10), patients undergoing
the Batista procedure (n  4), patients with an associated aortic
valve replacement (n  2), patients with postinfarction ventricular
septal defect closure (n  2), and a child previously operated on
for arterial switch repair for transposition of the great arteries with
a postischemic LV aneurysmectomy. The remaining 85 patients
were the subjects of the study.
Functional status was evaluated by using the New York Heart
Association (NYHA) classification, and quality of life was as-
sessed through a self-administered Minnesota Living With Heart
Failure (MLHF) questionnaire. From August through November
2003, survivors were invited to take part in a clinical survey, which
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
HF  heart failure
LV  left ventricular
LVEF  left ventricular ejection fraction
LVEqD  left ventricular end-diastolic equatorial
diameter
LVESVI left ventricular end-systolic volume index
MLHF Minnesota Living With Heart Failure
NYHA  New York Heart Association
SVR  surgical ventricular reverse remodelingincluded an echocardiographic evaluation. All deaths were classi-
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death certificates, and statements from witnesses). Death was con-
sidered caused by progressive HF in cases of onset and progression
of symptoms of definite HF. Sudden death was defined as death
within 1 hour of new symptoms or witnessed death without new
symptoms in the 72 hours preceding death. In-hospital mortality
included any death occurring during hospitalization.
Echocardiography
Echocardiographic studies were performed with a 2.5- or 3.5-MHz
transducer. Mitral regurgitation was assessed semiquantitatively as
grade 1 to 4 by means of color flow Doppler scanning. LVEF
and LV volumes were calculated by using a modified version of
Simpson’s rule.11 Preoperative data were obtained by reviewing
reports. Follow-up assessment consisted of a complete 2-dimensional
and Doppler echocardiographic study performed by a single operator
who had no knowledge of the patients’ clinical status.
Cardiac Catheterization
All patients underwent preoperative ventricular angiography in the
standard 30° right anterior oblique projection with injection of 0.7
mL/kg1 nonionic contrast medium at a rate of 12 mLs1 filmed
at 50 framess1. Ventricular volumes were calculated by using the
Chapman monoplane method,12 and anterior regional wall motion
was analyzed with the centerline method13 to distinguish akinetic
and dyskinetic segments. Regional wall motion was defined as
dyskinetic if the absolute motion of contiguous chords was less
than zero and akinetic if it was equal to zero. The LV end-diastolic
equatorial diameter (LVEqD) was measured as the LV transversal
diameter at the midpoint of the longitudinal axis between the
mitral plane and the LV apex on end-diastolic angioventriculo-
graphic frames. The mean of 3 measurements obtained during 3
different cardiac cycles was calculated for each patient and used
for the subsequent statistical analysis.
Operative Technique
The aim of the operation was to exclude all asynergic areas of the
ventricle, restoring a more physiologic elliptical geometry and LV
volume. All patients underwent SVR either through the Dor pro-
cedure or a modified Dor-type technique (without the Dacron
patch).14-16
Coronary artery bypass grafting, mitral valve repair or replace-
ment, biventricular pacing, and/or automatic cardioverter device
implantation were carried out as necessary. A single surgeon
performed most (82%) of the operations.
Statistical Analysis
Results are presented as mean values  standard deviation or
frequency percentages. Baseline and follow-up findings were com-
pared by using the Wilcoxon signed-rank nonparametric test for
continuous variables and the Fisher exact test for categoric vari-
ables. Because of the relatively small size of the sample and few
events, we estimated several Cox proportional hazard models of
analysis (no more than 6 variables at a time), removing and adding
each variable as a stepwise method to maximize the explained
variance of the model. At the end, we found 4 variables with a
cutoff point of a P value of .020 for further analyses (ejection
fraction, LVEqD, MLHF score, and akinesia-dyskinesia). A final
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selected significant variables at long-term mortality. Hazard ratios
and 95% confidence intervals were calculated. The Kaplan-Meier
survival curves were constructed for the significant predictors of
outcome, and differences were tested by using the log-rank test.
Statistical analysis was performed with SAS version 8.2 (SAS
Institute, Inc, Cary, NC) and SPSS version 9.0 (SPSS Inc, Chi-
cago, Ill) software.
Results
Study Population
The characteristics of the 85 patients are summarized in
Table 1 and Appendix E1. Fifty-six (65.9%) patients were
in NYHA functional class III or IV. Ventricular volumes
were severely enlarged. Most of the patients underwent
associated procedures: coronary artery bypass grafting in 82
(96.5%) patients and mitral valve correction in 16 (18.8%)
patients (repair in 15 and replacement in 1). Biventricular
pacing, automatic cardioverter device implantation, or both
were carried out in 2 (2.4%) patients.
Clinical Outcomes
Six (7.1%) patients died in the hospital: 1 during the oper-
ation and 5 in the intensive care unit a mean of 6.5 days after
the operation. The causes of death were low output syn-
drome in 4 patients and associated ventricular arrhythmia in
2 patients. The mean intensive care unit length of stay was
4.4  7.6 days.
The 79 patients discharged were followed up for a mean
of 43.7 months (range, 3-144 months). During this period,
14 patients died after a mean of 741 days: the causes of
death were progressive HF (n  5), sudden death (n  4),
acute myocardial infarction (n  1), ruptured abdominal
aortic aneurysm (n  1), pneumonia (n  1), cancer (n 
1), and septic shock (n 1). None of the patients underwent
transplantation. The survival rates after 1, 3, 5, and 10 years
were 89%, 79%, 75%, and 75%, respectively. There were
TABLE 1. Patient characteristics
Age, y (range) 60.5 9 (37-78)
Male/female sex 70/15
Prevalent HF, no. of patients (%) 71 (83.5)
Angina, no. of patients (%) 46 (54.1)
Isolated angina 14 (16.5)
Angina  prevalent HF 32 (37.6)
Mean NYHA class 2.9 1.0
NYHA class IV, no. of patients (%) 26 (30.6)
LVEF % (range) 27.6 6.3 (14-35)
LVESVI 90 mL/m2, no. of patients (%) 47 (55.3)
Mitral regurgitation (moderate-severe),
no. of patients (%)
16 (18.9)
Dyskinesia/akinesia 46/39
HF, Heart failure; NYHA, New York Heart Association; LVEF, left ventricular
ejection fraction; LVESVI, left ventricular end-systolic volume index.no sex differences in outcomes.
The Journal of ThoraciA symptomatic improvement was noted in most of the
survivors: the NYHA functional class decreased from 2.9
1.0 to 1.3  0.5 (P  .0001), and the MLHF score de-
creased from 44.2  21.5 to 24.1  15.5 (P  .0001).
Preoperative Predictors of Survival
The enlarged LVEqD had an inverse proportional relation-
ship with the outcome of SVR. Although the equator is a
continuous variable, the logistic analysis showed, among
the other possible figures, a bifurcation into less than 70 mm
and greater than 70 mm, which was particularly significant
as a determinant of prognosis (P . 0001). Amid all of the
diameters and volumes, an LVEqD of 70 mm or greater was
the most important predictor of mortality, increasing the
hazard of death by approximately 4.5 times. Segmental
akinesia was also a major predictor of outcome, with a
3.5-time increase in the risk of death (Table 2).
Survival at each time point was significantly better in
patients with an LVEqD of less than 70 mm and in
patients with dyskinesia versus akinesia (Figure 1). The
association of an enlarged LVEqD and segmental akine-
sia carried the poorest prognosis: survival in this group
was 18% versus 88% in the group with dyskinesia and an
LVEqD of less than 70 mm. Mitral valve surgery was not
a risk factor (P  .267).
Postoperative LV Reverse Remodeling
The 65 survivors were contacted from November 2003
through February 2004. Mean echocardiographic LVEF im-
proved from 27.6%  6.3% to 43.0%  10.1% (P 
.0001). LV end-diastolic volume index decreased from
131.6  34.7 to 92.8  51.2 mL/m2 (P  .0001), and LV
end-diastolic diameter index decreased from 35.3  5.5 to
33.0  13.7 mm/m2 (P  .0001). Furthermore, LV end-
systolic volume index (LVESVI) decreased from 89.6 
27.6 to 56.5  34.5 mL/m2 (P  .0001), and LV end-
systolic diameter index decreased from 28.14  5.15 to
26.9  12.6 mm/m2 (P  .04). These favorable changes
were less marked and did not reach statistical significance
among the patients in the highest LVEqD quartile (70
TABLE 2. Hazard ratio of prognostic factors affecting
survival
Hazard ratio P Values
95% Confidence
interval
LVEqD 5.28 .020 1.79-11.71
MLHF 0.93 .1742 0.070-1.06
LVEF 1.01 .2748 0.86-1.13
Akinesia 4.46 .024 1.23-17.12
LVEqD, Left ventricular equatorial diastolic diameter; MLHF, minnesota
living with heart failure score; LVEF, left ventricular ejection fraction.mm), whereas they were highly significant in those with an
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volumes decreased similarly in the presence of akinesia or
dyskinesia (Table 4).
Discussion
SVR in ischemic cardiomyopathy is a procedure refined
over the years,6,7,17 the retrospective evaluations of which
demonstrated a significant clinical benefit over time.9,18 Our
data confirm the effectiveness of SVR. The majority of
patients reported improvement in quality of life with a 75%
survival after 10 years; however, the efficacy of SVR in
ischemic cardiomyopathy versus medical therapy is de-
bated. In the last 2 decades, randomized clinical trials have
documented the beneficial effects on survival of angioten-
sin-converting enzyme (ACE) inhibitors, -blockers, aldo-
sterone antagonists, and angiotensin receptor blockers in
patients with HF and decreased LVEF. Recent pathophysi-
ologic evidence supported the concepts that LV remodeling
is related to clinical outcome and that ACE inhibitors,19
AT1 receptor antagonists,20 and -blockers21-24 slow or
reverse the progression of ventricular remodeling. However,
TABLE 3. Comparison of preoperative and follow-up clini
equatorial diameter
LVEqD <70 mm
Preoperative Follow-up
NYHA 2.8 1.0 1.3 0.5
MLHF score 49.3 21.7 23.9 16.8
LVEF, % 27.5 6.1 43.4 10.6
LVEDDI, mm/m2 34.4 5.9 31.2 4.3
LVESDI, mm/m2 27.1 5.6 25.0 5.8
LVEDVI, mL/m2 124.2 30.3 87.4 29.2
LVESVI, mL/m2 83.3 22.7 52.4 23.7
LVEqD, Left ventricular equatorial diastolic diameter; NYHA, New York Hea
ejection fraction; LVEDDI, left ventricular end-diastolic diameter index;
end-diastolic volume index; LVESVI, left ventricular end-systolic volume index.
360 The Journal of Thoracic and Cardiovascular Surgery ● Febravailable data on reverse remodeling in ischemic cardiomy-
opathy are limited to 18 months of treatment and document
reductions in LV end-systolic volume in a mean range of
12.7%.21-24
The reverse remodeling with the surgical approach in
conjunction with medical therapy led in the Reconstructive
Endoventricular Surgery returning Torsion Original Radius
Elliptical shape to the left ventricle (RESTORE) study to a
decrease in LVESVI of 36% of the preoperative values.
Eighty-six percent of our patients were taking ACE inhib-
itors and 66% were taking -blockers at follow-up, and the
decrease in LVESVI was 37%. Although the influence of
medical treatment on survival and remodeling remains an
unresolved factor, our data highlight the relevance for sur-
gical outcome of the equatorial zone of the left ventricle and
stress the negative synergism between an increased LVEqD
and segmental akinesia.
The relevance of the equatorial zone of the left ventricle
finds theoretic support in studies concerning the structural
changes that take place in ischemic cardiomyopathy during
acquisition of spherical shape in the failing heart. We are
Figure 1. Survival curves: dyski-
netic with low versus high left
ventricular end-diastolic equa-
torial diameter and akinetic
with low versus high left ven-
tricular end-diastolic equatorial
diameter. Pts, Patients at risk; P,
log-rank test for all groups.
and echocardiographic characteristics by left ventricular
LVEqD >70 mm
ue* Preoperative Follow-up P value *
01 2.9 1.1 1.5 0.8 .026
01 42.7 25.2 25.7 18.6 .16
01 22.4 6.4 38.4 11.2 .002
2 38.7 5.4 42.1 32.4 .17
31.7 5.1 35.7 27.1 .79
01 157.2 39.8 117.5 105.9 .10
01 111.4 34.1 77.2 66.1 .09
sociation; MLHF, Minnesota living with heart failure; LVEF, left ventricular
DI, left ventricular end-systolic diameter index; LVEDVI, left ventricularcal
P val
.00
.00
.00
.00
.01
.00
.00
rt As
LVES*Wilcoxon signed-rank test.
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myofibril orientation from oblique to transverse disposition
caused by the loss of elliptical shape that results in a
diminishing function, which in turn causes more enlarge-
ment with deeper geometric (spherical) consequence.25 This
plays a complementary negative role to the augmented
cardiac wall stress caused by the enlarged chamber, with all
the well-known adverse consequences. Thus far, the sphe-
ricity index could have a prominent part in candidates for
SVR, and LVEqD can be a surrogate that reflects changes
toward sphericalization of the left ventricle.26 In line with
this, we found that preoperative LVEqD correlated best with
outcome, whereas LV internal end-diastolic diameter (mea-
sured by means of echocardiography at the level of the basal
segments) was not significantly related to prognosis.
Among all of the LV diameters and volumes, LVEqD was
the only independent factor of clinical outcome. In patients
with an LVEqD of 70 mm or greater, the inconsistent
changes in volumes and diameters underline the unpredict-
ability of LV remodeling in such cases. We wonder whether
a certain value of LVEqD could represent a point of no
return for SVR. The Dor procedure, although reducing the
longitudinal axis while reshaping the apex, does not signif-
icantly reduce the short axis (equatorial diameter), despite
the oblique position of patch toward the septum,6,7,27,28 and
hence does not positively affect the sphericity index of the
left ventricle. The enlarged LVEqD could possibly be the
Achilles’ heel of the Dor procedure.
Other inferences, with clinical consequences, can be
drawn from geometric considerations related to LVEqD
more than to the LV volume itself. The ventricular equator
is the region in which maximum tension is generated during
systole and is also the fulcrum of the twisting and untwist-
ing of myocardial fibers.29-31 Moreover, because the papil-
lary muscles are inserted in the equatorial region, they tend
to migrate laterally in a spherical ventricle and cause ensu-
TABLE 4. Comparison of preoperative and follow-up clini
motion status
Dyskinesia
Preoperative Follow-up
NYHA 2.6 1.0 1.2 0.5
MLHF score 45.8 21.3 23.0 16.7
LVEF, % 28.5 6.1 44.5 11.6
LVEDDI, mm/m2 34.7 6.4 33.3 17.4
LVESDI, mm/m2 27.4 6.2 26.6 15.5
LVEDVI, mL/m2 130.0 40.9 91.2 37.7
LVESVI, mL/m2 86.4 32.1 55.5 40.5
LVEqD, Left ventricular equatorial diastolic diameter; NYHA, New York Hea
ejection fraction; LVEDDI, left ventricular end-diastolic diameter index;
end-diastolic volume index; LVESVI, left ventricular end-systolic volume ining functional mitral regurgitation.26 On the other end, a
The Journal of Thoracinumber of surgical series have indicated preoperative LV
volumes as one of the most important determinants of
clinical outcome.32,33 The RESTORE investigators have
recently stressed the prognostic relevance of preoperative
LV volumes.9 In this study the conventional predictors of
HF outcome (advanced age, functional class, and LVEF,
together with LVESVI) were predictive of survival. Con-
versely, in our analysis taking into account LVEqD, as we
saw in the correlation matrix, neither LV volume nor LVEF
was an independent risk factor. A reasonable explanation
for this discrepancy is that at similarly increased volumes,
uniform or regional remodeling might be the substrate of
different ventricular shapes and lead to different outcomes.
Furthermore, we could speculate that reductions in LVEF
observed in our patients could be related more to the loss of
proper myocardial fiber geometric orientation than to real
contraction impairment.
Concerning the second issue, the negative synergism
between the increased LVEqD and segmental akinesia, pre-
vious studies have reported better results or no difference in
outcome between patients with dyskinetic and those with
akinetic segments.6,7,9,34-36 Successful SVR comes from the
effective exclusion of the nonfunctional area, a process that
is critically dependent on demarcation. Although it has been
suggested that the extent of the scar is more important than
the type of wall motion (asynergia or dyskinesia),6 in our
patients an akinetic segment was an independent predictor
of poor outcome, with a 4-fold increase in the risk of death.
Dyskinetic scar and akinetic tissue both indicate abnormal
conditions characterized by the absence of functional tissue,
but surely there is less of a consensus regarding the physi-
ologic consequences of volume reduction through exclusion
of akinetic wall segments. After myocardial infarction, the
material properties of the affected wall vary. This is partic-
ularly true after the advent of thrombolysis, direct percuta-
neous transluminal angioplasty, or both that more fre-
nd echocardiographic characteristics by segmental wall
Akinesia
alue* Preoperative Follow-up P value*
0001 2.9 1.0 1.5 0.5 .0001
0001 46.8 19.9 26.1 16.4 .0001
0001 25.9 6.4 39.5 9.5 .0001
61 35.5  4.6 32.5 4.9 .01
74 28.6  4.7 27.3 4.1 .74
0001 129.1 30.9 88.8 40.9 .0001
0001 89.6 21.5 58.2 23.3 .0001
sociation; MLHF, Minnesota living with heart failure; LVEF, left ventricular
DI, left ventricular end-systolic diameter index; LVEDVI, left ventricular
*Wilcoxon signed-rank test.cal a
P v
.
.
.
.
.
.
.
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LVESquently cause subendocardial necrosis or patchy trabecular
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tween this akinetic region with the rest of the myocardium
could be less predictable than that of the compliant dyski-
netic scar, which should explain the reported equivocal
effect of akinetic scar resection on systolic and diastolic
properties.36 Although an independent predictor of out-
come, akinesia was most deleterious in patients with an
enlarged LVEqD, delimiting a subgroup with a particularly
poor prognosis.
In conclusion, this study included a broad spectrum of
patients ranging from classical LV aneurysm resection (dys-
kinetic) and resection of nonaneurysmal (akynetic) LV wall
muscle in severely dilated chamber. Even if, in this setting,
the term SVR (especially in the past) could be misleading,
it includes a grey area where is difficult to foresee the
degree of dilation residual to surgical resection. Hence
LVEqD might preoperatively help in estimating the residual
left ventricle and could also contain part of the answer to the
tantalizing dilemma of having the same preoperative vol-
umes but different outcome.
Study Limitations
Ours was a retrospective cohort analysis and has the inher-
ent limitations of this design. The study population was
relatively small, but the group was homogeneous, and the
majority of patients presented with advanced HF.
The angiographic assessment of LVEqD is invasive and
was not performed during the follow-up. Preoperative echo-
cardiographic analyses of LVEqD were not available be-
cause the echocardiographic assessments were not recorded
in most cases. We acknowledge that the postoperative
LVEqD measurement would be extremely important for
drawing conclusions regarding the surgical objective of
treating the form and not just the evident disease. At the
same time, we understand that this study might be of some
value as a stimulus for further investigations.
We did not have any consistent information concerning
preoperative myocardial viability. Although the majority of
the patients had undergone radionuclide scanning or an
echocardiographic stress test, the techniques used over the
years were so disparate that it was decided to exclude this
evaluation from the analysis.
Conclusions
The results of this study provide further evidence of the
effectiveness of SVR in patients with severe ischemic car-
diomyopathy. A careful preoperative assessment might
identify the optimal candidates for this procedure, and the
ongoing Surgical Treatment for Ischemic Heart Failure trial
will provide more insights into this intriguing matter. We
retrospectively assessed the ability of LVEqD, a reliable and
easy-to-assess parameter, to affect survival, particularly
when associated with segmental akinesia. For our patients
362 The Journal of Thoracic and Cardiovascular Surgery ● Febrwith severe ischemic dilated cardiomyopathy, an LVEqD of
less than 70 mm anticipated successful SVR. Surgical ma-
neuvers in ischemic cardiomyopathy have thus far corrected
LV apex abnormalities by means of SVR and LV base
dilatation by using undersized mitral rings. Our results
suggest the importance of adding the LVeqD measurements
to our diagnostic criteria and considering the LV equatorial
region a possible target of surgical correction.
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Patient characteristics and stepwise regression for variable
selection (n  85)
P
value
Age, y (range) 60.5 9 (37-78) .189*
Sex, M/F 70/15 .321
Obesity, no. of patients (%) 11 (12.9) .080*
BMI 26.0 3.1 .386
Prevalent HF, no. of patients (%) 71 (83.5) .961
Angina, no. of patients (%) 46 (54.1) .542
Isolated angina 14 (16.5) .356
Angina  prevalent HF 32 (37.6) .375
Cardiogenic shock, no. of patients (%) 9 (10.6) .951
NYHA (Class) 2.9 1.0 .612
NYHA class I, no. of patients (%) 9 (10.6) .841
NYHA class II, no. of patients (%) 20 (23.5) .654
NYHA class III, no. of patients (%) 30 (35.3) .259
NYHA class IV, no. of patients (%) 26 (30.6) .345
MLHF score 44.2 21.5 .153*
Prior cardiac surgery, no. of patients (%) 6 (7.1) .987
PVD, no. of patients (%) 24 (28.2) .746
AMI, no. of patients (%) 82 (96.5) .598
AMI 90 days, no. of patients (%) 17 (20.0) .243
IABP, no. of patients (%) 9 (10.6) .954
Echocardiographic parameters
LVEF, % (range) 27.6 6.3 (14-35) .054*
14%-19%, no. of patients (%) 8 (9.5)
20%-25%, no. of patients (%) 39 (45.9)
26%-35%, no. of patients (%) 38 (44.7)
2LVEDDI, mm/m 35.3 5.5 .785
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value
LVESDI, mm/m2 28.1 5.1 .687
LVEDVI, mL/m2 131.6 34.7 .451
LVESVI, mL/m2 89.6 27.6 .259
Mitral regurgitation (moderate-severe),
no. of patients (%)
16 (18.9) .958
Angiography
LVEqD 63.8 7.03 .032*
Dyskinesia-akinesia 46/39 .005*
Coronary disease, no. of patients (%) 82 (96.5) .942
One vessel 19 (22.4) .657
Two vessel 16 (18.8) .248
Three vessel 47 (55.3) .364
Left main stenosis, no. of patients (%) 13 (15) .855
Intraoperative
Prophylactic IABP, no. of patients (%) 29 (34.1) .621
Crossclamp time 94.4 34.2 .254
CPB time 155.3 64.6 .547
Medication at follow-up (65 patients)
-Blockers, % 66 .318
ACE inhibitors, % 86 .412
BMI, Body mass index; HF, heart failure; NYHA, New York Heart Associ-
ation; MLHF, Minnesota living with heart failure; PVD, peripheral vascular
disease; AMI, acute myocardial infarction; IABP, intra-aortic balloon pump;
LVEF, left ventricular ejection fraction; LVEDDI, left ventricular end-
diastolic diameter index; LVESDI, left ventricular end-systolic diameter
index; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left
ventricular end-systolic volume index; LVEqD, left ventricular equatorial
diastolic diameter; CPB, cardiopulmonary bypass; ACE, angiotensin-con-
verting enzyme. *Variables with a P value of.20 or less were selected for
the final regression model.
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